Human EBV VCA IgM ELISA kit is intended for analysing in-vitro quantitative amounts of human IgM antibodies to Epstein–Barr virus viral-capsid antigen (EBV VCA IgM) using samples of plasma or serum. This assay has a minimum analytical sensitivity limit of 0.86 U/ml.
Epstein–Barr virus viral-capsid antigen (EBV-VCA) is a target for the anti-VCA antibodies and is important for the viral capsid of the Epstein–Barr virus (EBV). Anti-VCA antibodies have played a vital role in the diagnosis of infectious mononucleosis. An abnormal result is an indication of either a current or a past EBV infection. The three antibodies which are useful in the test include viral capsid antigen (VCA) IgG, VCA IgM and the Epstein-Barr nuclear antigen (EBNA). The presence of VCA IgG antibodies can indicate that an EBV infection has occurred recently or in the past. Whereas the presence of VCA IgM antibodies along with the absence of EBNA indicate a recent occurrence of the infection. The detection of antibodies to EBNA indicate an infection which occurred in the past (since EBNA develop 6-8 weeks after the time of infection). In cases with primary infections, the sensitivity of anti-VCA IgM and anti-VCA IgG have been estimated to be 100% reliable.
EBV VCA IGM ELISA KIT CONTENT
All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.
- Calibrator A (Negative Control).
- Calibrator B (Cut-Off Standard).
- Calibrator C (Weak Positive Control).
- Calibrator D (Positive Control).
- Sample Diluent.
- Enzyme Conjugate.
- TMB Substrate.
- Stop Solution.
- Washing Buffer (10x).
- EBV VCA coated microtiter strips.
The minimum detection sensitivity level of IgM directed to Epstein–Barr virus viral-capsid antigen (EBV VCA IgM) using current human EBV VCA-IgM ELISA kit was 0.86 U/ml. The dynamic range for this assay is 1.0 – 150.0 U/ml.
– EBV VCA ELISA: IgM
– Intra-Assay-Precision: 7.0 %
– Inter-Assay-Precision: 6.3 – 12.1 %
– Inter-Lot-Precision: 2.7 – 10.8 %
– Analytical Sensitivity: 0.86 U/mL
– Recovery: 113 – 119 %
– Linearity: 78 – 118 %
– Cross-Reactivity: No cross-reactivity to Mumps, Varicella and Measles.
– Interferences: No interferences to bilirubin up to 0.3 mg/mL, hemoglobin up to 8.0 mg/mL and triglycerides up to 5.0 mg/mL.
– Clinical Specificity: 100 %
– Clinical Sensitivity: 98 %
- Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis. J Clin Virol. (2007) 38 (4): 292-7. Nystad T.W. and Myrmel H.
- Epstein-Barr virus serology in bone marrow transplantations: a one-year retrospective study with detection of EBV IgM-VCA-specific antibodies. J Med Virol. (1986) 18 (4): 349-60. Morinet F., et al.
- Evaluation of Epstein-Barr virus antibodies, anti-VCA avidity by immunofluorescence and immunoblot assays for assessment of Epstein-Barr virus immunologic state. J Virol Methods. (2009) 159 (2): 300-2. Sener A.G., et al.
- Evaluation of four commercial systems for the diagnosis of Epstein-Barr virus primary infections. Clin Vaccine Immunol. (2011) 18 (3): 444-8. de Ory F., et al.
- Evaluation of the Architect Epstein-Barr Virus (EBV) viral capsid antigen (VCA) IgG, VCA IgM, and EBV nuclear antigen 1 IgG chemiluminescent immunoassays for detection of EBV antibodies and categorization of EBV infection status using immunofluorescence assays as the reference method. Clin Vaccine Immunol. (2014) 21 (5): 684-8. Corrales I., et al.
- Full Name: EBV VCA IgM ELISA Kit
- Reactivity: Human
- Sample Type: Serum, Plasma
- Sensitivity: 0.86 U/ml